Paraneoplastic cerebellar degeneration

Handbook of Clinical Neurology

Volumn 103, Issue , 2012, Pages 215-223

  Vernino, Steven ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961145519     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-51892-7.00013-9     Document Type: Chapter

References (50)

1. Albert M.L., Austin L.M., Darnell R.B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000, 47:9-17.
2. Antoine J.C., Cinotti L., Tilikete C., et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000, 48:105-108.
3. Bataller L., Wade D.F., Graus F., et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62:778-782.
4. Bernal F., Shams'ili S., Rojas I., et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003, 60:230-234.
5. Brain W., Daniel P., Greenfield J. Subacute cortical cerebellar degeneration and its relation to carcinoma. J Neurol Neurosurg Psychiatry 1951, 14:59-75.
6. Brashear H.R., Greenlee J.E., Jaeckle K.A., et al. Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms. Neurology 1989, 39:1605-1609.
7. Brock S., Ellison D., Frankel J., et al. Anti-Yo antibody-positive cerebellar degeneration associated with endometrial carcinoma: case report and review of the literature. Clin Oncol (R Coll Radiol) 2001, 13:476-479.
8. Candler P.M., Hart P.E., Barnett M., et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004, 75:1411-1415.
9. Chan K., Vernino S., Lennon V. ANNA-3 anti-neuronal nuclear antibody marker of lung cancer-related autoimmunity. Ann Neurol 2001, 50:301-311.
10. Clouston P.D., Saper C.B., Arbizu T., et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 1992, 42:1944-1950.
11. Cocconi G., Ceci G., Juvarra G., et al. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. A case report. Cancer 1985, 56:2318-2320.
12. Dalmau J., Gultekin S.H., Voltz R., et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999, 122:27-39.
13. Darnell J.C., Albert M.L., Darnell R.B. Cdr2, a target antigen of naturally occurring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000, 60:2136-2139.
14. Darnell R.B., Albert M.L. cdr2-specific CTLs are detected in the blood of all patients with paraneoplastic cerebellar degeneration analyzed. Ann Neurol 2000, 48:270-271.
15. Darnell R.B., Posner J.B. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1554.
16. Eerola A.K., Soini Y., Paakko P. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 2000, 6:1875-1881.
17. Fukuda T., Motomura M., Nakao Y., et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003, 53:21-28.
18. Galanis E., Frytak S., Rowland K.M., et al. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. Cancer Immunol Immunother 1999, 48:85-90.
19. Giometto B., Marchiori G.C., Nicolao P., et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 1997, 23:468-474.
20. Graus F., Keime-Guibert F., Rene R., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148.
21. Graus F., Lang B., Pozo-Rosich P., et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002, 59:764-766.
22. Greenfield J. Subacute spino-cerebellar degeneration occurring in elderly patients. Brain 1934, 57:161-176.
23. Greenlee J.E., Brashear H.R. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983, 14:609-613.
24. Hammack J.E., Kimmel D.W., O'Neill B.P., et al. Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc 1990, 65:1423-1431.
25. Hammack J., Kotanides H., Rosenblum M.K., et al. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992, 42:1938-1943.
26. Hetzel D.J., Stanhope C.R., O'Neill B.P., et al. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clinic Proc 1990, 65:1558-1563.
27. Keime-Guibert F., Graus F., Fleury A., et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000, 68:479-482.
28. Kiers L., Altermatt H.J., Lennon V.A. Paraneoplastic anti-neuronal nuclear IgG autoantibodies (type I) localize antigen in small cell lung carcinoma. Mayo Clin Proc 1991, 66:1209-1216.
29. Konarski J.Z., McIntyre R.S., Grupp L.A., et al. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. J Psychiatry Neurosci 2005, 30:178-186.
30. Land R., Carter J., Houghton R., et al. Gynaecology meets neurology: paraneoplastic cerebellar degeneration. Aust N Z J Obstet Gynaecol 2005, 45:79-81.
31. Levisohn L., Cronin-Golomb A., Schmahmann J.D. Neuropsychological consequences of cerebellar tumour resection in children: cerebellar cognitive affective syndrome in a paediatric population. Brain 2000, 123:1041-1050.
32. Lucchinetti C.F., Kimmel D.W., Lennon V.A. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998, 50:652-657.
33. Mowzoon N., Bradley W.G. Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: a case report. J Neurol Sci 2000, 178:63-65.
34. Oguro-Okano M., Griesmann G.E., Wieben E.D., et al. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc 1992, 67:1150-1159.
35. Paslawski T., Duffy J., Vernino S. Speech and language findings associated with paraneoplastic cerebellar degeneration. Am J Speech Lang Pathol 2005, 14:200-207.
36. Peterson K., Rosenblum M.K., Kotanides H., et al. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
37. Pittock S.J., Lucchinetti C.F., Lennon V.A. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003, 53:580-587.
38. Pittock S.J., Kryzer T.J., Lennon V.A. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004, 56:715-719.
39. Rewcastle N. Subacute cerebellar degeneration with Hodgkin's disease. Arch Neurol 1963, 9:407-413.
40. Rojas I., Graus F., Keime-Guibert F., et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000, 55:713-715.
41. Rojas-Marcos I., Rousseau A., Keime-Guibert F., et al. Spectrum of paraneoplastic neurological disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003, 82:216-223.
42. Shams'ili S., Grefkens J., de Leeuw B., et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003, 126:1409-1418.
43. Sillevis Smitt P., Kinoshita A., De Leeuw B., et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000, 342:21-27.
44. Stark E., Wurster U., Patzold U., et al. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 1995, 52:814-818.
45. Trotter J., Hendin B., Osterland K. Cerebellar degeneration with Hodgkin disease: an immunological study. Arch Neurol 1976, 33:660-661.
46. Vernino S., Lennon V.A. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000, 47:297-305.
47. Vernino S., O'Neill B.P., Marks R.S., et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004, 6:55-62.
48. Voltz R., Gultekin S.H., Rosenfeld M.R., et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999, 340:1788-1795.
49. Yu Z., Kryzer T., Griesmann G., et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146-154.
50. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.